Ac-SDKP vs Teduglutide

Inhibits hematopoietic stem cell entry into S-phase. Blocks TGF-β1-mediated fibroblast activation, reducing collagen deposition. Promotes angiogenesis via VEGF upregulation. Regulated in vivo by ACE enzyme.

Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) is an endogenous tetrapeptide generated from the N-terminus of thymosin beta-4 by the enzyme prolyl oligopeptidase, with further regulation by angiotensin-converting enzyme (ACE), and is characterized by roles in hematopoietic progenitor regulation and anti-fibrotic signaling in renal, cardiac, and vascular tissue. Ac-SDKP inhibits collagen synthesis and fibroblast proliferation, reduces TGF-beta-1-mediated fibrotic signaling, and promotes anti-inflammatory macrophage polarization in preclinical models, suggesting a role in tissue homeostasis downstream of the thymosin beta-4 pathway. Preclinical studies in rodent models of renal fibrosis and systemic lupus erythematosus — predominantly from the NIH-funded Rhaleb and Carretero laboratory at Henry Ford Health — have demonstrated that exogenous Ac-SDKP reduces collagen deposition and inflammatory infiltrate; no human clinical trials have been completed or indexed in PubMed. Ac-SDKP has no FDA approval and no approved indication in any jurisdiction; it is studied as a research compound with a plausible anti-fibrotic mechanism and consistent preclinical evidence, but extrapolation of rodent findings to human therapeutic outcomes has not been validated by any clinical investigation.

GLP-2 receptor agonist; stimulates intestinal epithelial proliferation and reduces apoptosis; increases intestinal blood flow and inhibits gastric motility

Teduglutide (Gattex in the United States, Revestive in the European Union) is a GLP-2 analogue and FDA-approved prescription medication indicated for short bowel syndrome (SBS) with intestinal failure in adults and pediatric patients, designed to reduce dependence on parenteral nutrition and intravenous fluids by promoting intestinal mucosal growth and enhancing residual bowel absorptive capacity. By activating GLP-2 receptors on intestinal subepithelial myofibroblasts and enteric neurons, teduglutide stimulates paracrine release of insulin-like growth factor 1 (IGF-1) and keratinocyte growth factor (KGF), driving enterocyte crypt cell proliferation, increasing villus height, and expanding mucosal absorptive surface area to improve nutrient and fluid absorption from functionally compromised residual bowel. A systematic review and meta-analysis of Phase 3 registrational trial data published in the Journal of Parenteral and Enteral Nutrition documented significant reductions in parenteral nutrition volume requirements, and long-term follow-up data published in Clinical and Translational Gastroenterology confirmed durable reductions in parenteral support needs over extended treatment periods. Teduglutide is an FDA-approved prescription medication; it is indicated for adults and pediatric patients (≥1 year) with SBS dependent on parenteral support, and use outside this indication or without physician supervision is not supported by established safety and efficacy data.